Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PCVX 
Vaxcyte Inc (PCVX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/12/2025: PCVX (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $114.88
1 Year Target Price $114.88
| 9 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 28.81% | Avg. Invested days 47 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/12/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.85B USD | Price to earnings Ratio - | 1Y Target Price 114.88 |
Price to earnings Ratio - | 1Y Target Price 114.88 | ||
Volume (30-day avg) 10 | Beta 1.21 | 52 Weeks Range 27.66 - 121.06 | Updated Date 08/12/2025 |
52 Weeks Range 27.66 - 121.06 | Updated Date 08/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.11 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-12 | When - | Estimate -1.17 | Actual -1.22 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -16.44% | Return on Equity (TTM) -21.65% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2278873409 | Price to Sales(TTM) - |
Enterprise Value 2278873409 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -14.43 | Shares Outstanding 129823000 | Shares Floating 116744950 |
Shares Outstanding 129823000 | Shares Floating 116744950 | ||
Percent Insiders 0.67 | Percent Institutions 116.48 |
Upturn AI SWOT
Vaxcyte Inc
Company Overview
History and Background
Vaxcyte, Inc. was founded in 2013. It is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of infectious diseases.
Core Business Areas
- Vaccine Development: Vaxcyte focuses on developing novel and improved vaccines using its cell-free protein synthesis platform. Its primary focus is on preventing or treating infectious diseases.
Leadership and Structure
Grant Pickering is the CEO. The company has a board of directors and a leadership team focused on research, development, and commercialization.
Top Products and Market Share
Key Offerings
- PCV20: Vaxcyte's lead candidate is PCV20, a 20-valent pneumococcal conjugate vaccine targeting Streptococcus pneumoniae. Market share is currently zero, as it's in development. Competitors include Pfizer (Prevnar 20) and Merck.
- Vaxcyte's second program: is VAX-A1, a vaccine to prevent Group A Strep. Market share is currently zero, as it's in development. Competitors include multiple firms developing Group A strep vaccines.
Market Dynamics
Industry Overview
The vaccine market is substantial and growing, driven by increased awareness of preventative healthcare and emerging infectious diseases. Advancements in vaccine technology and manufacturing are key trends.
Positioning
Vaxcyte aims to compete by developing more effective and convenient vaccines using its cell-free technology. Its competitive advantage lies in potentially improved immunogenicity and manufacturability.
Total Addressable Market (TAM)
The pneumococcal vaccine market is estimated to be multi-billion dollar. Vaxcyte's PCV20 targets a significant portion of this TAM. Group A Strep is also multi-billion dollar market.
Upturn SWOT Analysis
Strengths
- Cell-free protein synthesis platform
- Strong intellectual property portfolio
- Experienced management team
- Lead candidate PCV20 in clinical trials
Weaknesses
- No currently marketed products
- Reliance on successful clinical trial outcomes
- Limited financial resources compared to large pharma
- High R&D costs
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new vaccine targets
- Favorable regulatory environment
- Growing demand for preventative healthcare
Threats
- Clinical trial failures
- Competition from established vaccine manufacturers
- Patent challenges
- Changes in regulatory landscape
Competitors and Market Share
Key Competitors
- PFE
- MRK
Competitive Landscape
Vaxcyte aims to differentiate itself with potentially improved vaccines. Competes with large, established players like Pfizer and Merck.
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily driven by clinical trial progress and pipeline development.
Future Projections: Future growth depends on successful clinical trial outcomes and potential commercialization of PCV20 and other vaccine candidates.
Recent Initiatives: Advancing PCV20 through clinical trials, expanding pipeline with new vaccine targets, securing partnerships.
Summary
Vaxcyte is a clinical-stage company with a promising cell-free protein synthesis platform, driving its vaccine candidates forward. Its success hinges on positive clinical trial outcomes and competition in the vaccine industry is fierce, especially from established giants. Vaxcyte needs to carefully manage its resources and leverage strategic partnerships to maintain its trajectory.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Vaxcyte's website
- SEC filings
- Analyst reports
- Market research reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vaxcyte Inc
Exchange NASDAQ | Headquaters San Carlos, CA, United States | ||
IPO Launch date 2020-06-12 | Co-Founder, CEO & Director Mr. Grant E. Pickering M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 414 | Website https://vaxcyte.com |
Full time employees 414 | Website https://vaxcyte.com | ||
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.